New Cholesterol Guidelines Look for Long Lasting Results Part 3

Video

With a new class of drugs on the horizon questions remain about what PCSK9 inhibitors will mean to the future of cardiac care. Doctors are slowly learning the answers to those questions as possible approval draws closer.

With a new class of drugs on the horizon questions remain about what PCSK9 inhibitors will mean to the future of cardiac care. Doctors are slowly learning the answers to those questions as possible approval draws closer.

C. Noel Bairey Merz, MD, FACC, FAHA, from the Cedars Sinai Heart Institute discussed what the potential new medications can mean for patient treatment at the American College of Cardiology Scientific Sessions and Expo in San Diego.

Related Videos
Why Are Adult ADHD Cases Climbing?
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Optimizing Diabetes Therapies with New Classifications
Anthony Lembo, MD | Credit: Cleveland Clinic
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
© 2024 MJH Life Sciences

All rights reserved.